Chewy Gets FDA Warning About Unapproved Antimicrobial Animal Drugs
By Dean Seal
Chewy and eight other manufacturers and distributors of antimicrobial animal drugs have received warning letters from the Food and Drug Administration telling them that those medicines are unapproved and misbranded.
The agency said on Thursday that it's concerned that using the products, which contain antimicrobials that are important in human medicine, without medical oversight contributes to the development of antimicrobial resistance.
The FDA said it hasn't verified the safety or effectiveness of the products as part of an animal drug review process or facility inspections, and that the products are being illegally marketed over the counter. The products are marketed and labeled for minor species such as aquarium fish and pet birds, and contain antimicrobials including amoxicillin and penicillin.
Representatives for Chewy didn't immediately respond to a request for comment.
Among the other companies that received FDA warning letters were Kraft Drug and California Veterinary Supply.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 14, 2023 11:19 ET (16:19 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks